Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome

Study Overview
=================
Brief Summary
-----------------
Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year. Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh. Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited. Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.

Official Title
-----------------
Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort

Conditions
-----------------
Calciphylaxis

Intervention / Treatment
-----------------
* Other: Calcific Uremic Arteriolopathy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients ≥ 18 years with chronic renal failure with Glomerular Filtration Rate < 30ml/min/1,73m² diagnosis of calciphylaxis between 2006 and 2016 living in the Regions of Bretagne, Pays de la Loire, Poitou-Charentes or Centre Val de Loire. Exclusion Criteria: realized biopsy in favor of differential diagnosis significant arterial lesion of lesion area or differential diagnosis more valid if the diagnosis is not based on the following criteria: 3 clinical criteria or 2 clinical criteria and biopsy in favor, criteria which are : Patient in chronic hemodialysis or stade 4 chronic kidney disease At least 2 painful sores and hardly curable with concomitant painful purpura Sore and purpura localisation in trunk, extremities and penis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Calciphylaxis Cases<br>Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes | Other: Calcific Uremic Arteriolopathy<br> <br> |
| Witness cases<br>Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome. |  | Up to 16 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study factors determining the patient outcome with calciphylaxis |  | Up to 16 months | 
| Study case control of risk factors in the subgroup of patients in extra renal replacement therapy |  | Up to 16 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
calcific uremic arteriolopathy, case-control study, cohort study